A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products

References

1. 1.↵
   1. Knapp J.,
   2. Kushner H.

   Generalized Methodology for Evaluation of Parenteral Inspection Procedures. J. Parenter. Drug Assoc. 1980, 34 (1), 14–61.

   OpenUrlPubMed
2. 2.↵
   1. Melchore J. A.

   Sound Practices for Consistent Human Visual Inspection. AAPS PharmSciTech 2011, 12 (1), 215–221.

   OpenUrlPubMed
3. 3.↵
   1. Leversee R.L.,
   2. Shabushnig J.G.

   A Survey of Industry Practice for the Visual Inspection of Injectable Products (Preliminary Report). PDA Visual Inspection Forum, October 2008.
4. 4.↵
   1. Bukofzer S.,
   2. Ayers J.,
   3. Chavez A.,
   4. Devera M.,
   5. Miller J.,
   6. Ross D.,
   7. Shabushnig J.,
   8. Vargo S.,
   9. Watson H.,
   10. Watson R.

   There may be clinical circumstances where tighter AQL values (limits) may be appropriate for high-risk patients and for other routes of administration based on an evaluation of patient risk. Bukofzer S., Ayers J., Chavez A., Devera M., Miller J., Ross D., Shabushnig J., Vargo S., Watson H., Watson R. Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.

   OpenUrlFREE Full Text
5. 5.↵
   1. Knapp J. Z.,
   2. Budd G. W.

   Part II: Visible Inspection Data and the Sampling Inspection. PDA Annual Conference, April 4-6 2005, Chicago, IL.
6. 6.↵
   1. Taylor W. A.

   Guide to Acceptance Sampling; Taylor Enterprises, Lake Villa, Il 1992.
7. 7.↵
   1. Gershon M.

   Statistical Process Control for the Pharmaceutical Industry. J. Parenter. Sci. Technol. 1991, 45(1), 41–50.

   OpenUrlPubMed
8. 8.↵
   1. Guadagnion E.,
   2. Zuccato D.

   Delamination Propensity of Pharmaceutical Glass Containers by Accelerated Testing with Different Extraction Media. PDA J. Pharm. Sci. Technol. 2012, 66 (2), 116–125.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Jiang G.,
   2. Goss M.,
   3. Li G.,
   4. Jing W.,
   5. Shen H.,
   6. Fujimori K.,
   7. Le L.,
   8. Wong L.,
   9. Wen Z. Q.,
   10. Nashed-Samuel Y.,
   11. Riker K.,
   12. Germansderfer A.,
   13. Tsang P.,
   14. Ricci M.

   Novel Mechanism of Glass Delamination in Type 1A Borosilicate Vials Containing Frozen Protein Formulations. PDA J. Pharm. Sci. Technol. 2013, 67 (4), 323–335.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Lacocca R. G.,
    2. Toltl N.,
    3. Allgeier M.,
    4. Bustard B.,
    5. Dong X.,
    6. Foubert M.,
    7. Hofer J.,
    8. Peoples S.,
    9. Shelbourn T.

    Factors Affecting the Chemical Durability of Glass Used in the Pharmaceutical Industry. AAPS PharmSciTech 2010, 11 (3), 1340–1349.

    OpenUrlPubMed
11. 11.↵
    1. Sloey C.,
    2. Gleason C.,
    3. Phillips J.

    Determining the Delamination Propensity of Pharmaceutical Glass Vials Using a Direct Stress Method. PDA J. Pharm. Sci. Technol. 2013, 67 (1), 35–42.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Cash P.,
    2. Narwal R.,
    3. Levitskaya S. V.,
    4. Krause S.,
    5. Murphy D.,
    6. Mazaheri M.

    Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products. PDA J. Pharm. Sci. Technol. 2016, doi: 10.5731/pdajpst.2015.
13. 13.↵
    1. Saddic G.

    Challenges In Developing a Semi-Quantitative Visible Particulate Method for Routine Commercial Testing. 1st International Symposium on Higher Order Structure of Protein Therapeutics, Rockville, MD, September 27, 2011.
14. 14.↵
    United States Pharmacopeia. <790> Visible Particulates in Injections. United States Pharmacopeia–National Formulary; USP 37 NF 32, 2014.
15. 15.↵
    1. Wuchner K.,
    2. Büchler J.,
    3. Spycher R.,
    4. Dalmonte P.,
    5. Volkin D. B.

    Development of a Microflow Digital Imaging Assay to Characterize Protein Particulates during Storage of a High Concentration IgG1 Monoclonal Antibody Formulation. J. Pharm. Sci. 2010, 99 (8), 3343–3361.

    OpenUrlPubMed
16. 16.↵
    1. Das T. K.

    Protein Particulate Detection Issues in Biotherapeutics Development-Current Status. AAPS PharmSciTech 2012, 13 (2), 732–746.

    OpenUrlPubMed
17. 17.↵
    1. Singh S. K.,
    2. Afonina N.,
    3. Awwad M.,
    4. Bechtold-Peters K.,
    5. Blue J. T.,
    6. Chou D.,
    7. Cromwell M.,
    8. Krause H. J.,
    9. Mahler H. C.,
    10. Meyer B. K.,
    11. Narhi L.,
    12. Nesta D. P.,
    13. Spitznagel T.

    An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics. J. Pharm. Sci. 2010, 99 (8), 3302–3302.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Doesegger L.,
    2. Mahler H. C.,
    3. Szczesny P.,
    4. Rockstroh H.,
    5. Kallmeyer G.,
    6. Langenkamp A.,
    7. Herrmann J.,
    8. Famulare J.

    The Potential Clinical Relevance of Visible Particles in Parenteral Drugs. J. Pharm. Sci. 2012, 101 (8), 2635–2644.

    OpenUrlPubMed
19. 19.↵
    1. Bukofzer S.,
    2. Ayres J.,
    3. Chavez A.,
    4. Devera M.,
    5. Miller J.,
    6. Ross D.,
    7. Shabushnig J.,
    8. Vargo S.,
    9. Watson H.,
    10. Watson R.

    Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.

    OpenUrlFREE Full Text
20. 20.↵
    1. Melchore J. A.,
    2. Berdovich D.

    Considerations for Design and Use of Container Challenge Sets for Qualification and Validation of Visible Particulate Inspection. PDA J. Pharm. Sci. Technol. 2012, 66 (3), 273–284.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    FDA Guidance for Industry. Immunogenicity assessment for therapeutic protein product. August 2014. Accessed February 3, 2016; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.